Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report)'s stock price was down 3.3% on Tuesday . The company traded as low as C$2.65 and last traded at C$2.65. Approximately 28,572 shares changed hands during mid-day trading, a decline of 63% from the average daily volume of 76,766 shares. The stock had previously closed at C$2.74.
Medexus Pharmaceuticals Trading Up 2.2%
The firm has a market cap of C$63.58 million, a price-to-earnings ratio of 13.58 and a beta of 1.96. The stock has a 50-day moving average of C$2.95 and a two-hundred day moving average of C$2.97.
About Medexus Pharmaceuticals
(
Get Free Report)
Medexus Pharmaceuticals Inc, formerly Pediapharm Inc is a leading specialty pharmaceutical company with a strong North American commercial platform. It is focused on the therapeutic areas of auto-immune disease and pediatrics. The leading products are Rasuvo and Metoject, a unique formulation of methotrexate to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.
Featured Articles
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
